MedTrace Logo

Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema

NCT01893879 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-05-18

Study results available
· View outcomes & findings →

Summary

This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.

Conditions

  • Lymphedema
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

placebo for study drug

Given PO

DRUG

(RS)2-(3-benzoylphenyl)-propionic acid

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Stanley Rockson · Stanford University Hospitals and Clinics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01893879 on ClinicalTrials.gov